FDA approves new pain medication as an alternative to opioids: What to know about Journavx
The FDA on Thursday approved a new class of pain medication that provides an alternative to opioids. It will be sold under ...
Psychology Today14 小时
Treating Pain—Avoiding the Brain
A new class of non-opioid drugs treats pain by blocking signals before they reach the brain, reducing the risk of addiction.
FDA approves opiate-alternative acute pain management drug, local experts share their thoughts
On Wednesday, the U.S. Food and Drug Administration approved a new pain management drug which could change the way healthcare ...
FDA Approves the First Non-Opioid Pain Drug in 20 Years
The prescription pills, sold under the brand name Journavx and made by Vertex Pharmaceuticals, are taken twice a day and ...
InsideHook on MSN11 小时
New FDA Approval Could Transform Pain Management
It’s become a familiar tragedy: someone is prescribed pain medication to recover from an injury, then becomes addicted to the ...
FDA approves new type of nonopioid painkiller for acute pain
The Food and Drug Administration approved a new type of nonopioid painkiller, Journaxv, or suzetrigine, drugmaker Vertex ...
Everyday Health11 小时
FDA Approves First New Type of Pain Medication in More Than 20 Years
Suzetrigine, to be sold under the brand name Journavx, is the first new type of pain medicine approved by the FDA in more ...
What Is Journavx? First Pain Medication Approved by FDA in Over Two Decades
This milestone marks a breakthrough after unsuccessful attempts to develop painkillers without the addictive potential of opioids.
Vertex Pharmaceuticals' non-opioid pain medication gets FDA approval
A non-opioid pain medication made by Vertex Pharmaceuticals has received approval for adults from the Food and Drug ...
FDA approves new type of non-opioid pain medication
The U.S. Food and Drug Administration (FDA) approved Journavx (suzetrigine) oral tablets on Thursday as a first-in-class ...
Medscape16 小时
FDA OKs First-In-Class Nonopioid Pain Med Suzetrigine
Suzetrigine selectively inhibits the NaV1.8 pain-signaling pathway in the peripheral nervous system and provides effective ...